Jim Cramer: This Financial Stock Is A Buy, Core Scientific Is A 'Very Overvalued Situation'
Portfolio Pulse from Avi Kapoor
Jim Cramer recommends buying Ally Financial (ALLY) and considers Core Scientific (CORZ) overvalued. He is cautious on Snowflake (SNOW) and disappointed with Royalty Pharma (RPRX). Recent earnings and analyst actions are influencing these views.
August 16, 2024 | 1:28 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Jim Cramer considers Core Scientific overvalued despite recent gains and increased convertible note offering.
Cramer's view of the stock as overvalued, despite recent gains and increased convertible note offering, is likely to negatively impact the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
Jim Cramer is disappointed with Royalty Pharma following worse-than-expected quarterly results.
The disappointing earnings report and Cramer's negative sentiment are likely to negatively impact the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100
NEGATIVE IMPACT
Jim Cramer is cautious on Snowflake, and a recent downgrade by Wells Fargo adds to the negative sentiment.
Cramer's caution and the downgrade by Wells Fargo are likely to negatively impact the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Jim Cramer recommends buying Ally Financial following stronger-than-expected quarterly earnings.
Cramer's recommendation and the recent strong earnings report are likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100